286 related articles for article (PubMed ID: 22285382)
1. Paraoxonase activity in healthy, diabetic, and hemodialysis patients.
Gbandjaba NY; Ghalim N; Hassar M; Berrougui H; Labrazi H; Taki H; Saile R; Khalil A
Clin Biochem; 2012 Apr; 45(6):470-4. PubMed ID: 22285382
[TBL] [Abstract][Full Text] [Related]
2. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
[TBL] [Abstract][Full Text] [Related]
3. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population.
Gupta N; Binukumar BK; Singh S; Sunkaria A; Kandimalla R; Bhansali A; Gill KD
Gene; 2011 Nov; 487(1):88-95. PubMed ID: 21803130
[TBL] [Abstract][Full Text] [Related]
4. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation.
Serhatlioglu S; Gursu MF; Gulcu F; Canatan H; Godekmerdan A
Cell Biochem Funct; 2003 Dec; 21(4):371-5. PubMed ID: 14624476
[TBL] [Abstract][Full Text] [Related]
5. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
6. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract.
Hashim Z; Zarina S
Clin Biochem; 2007 Jun; 40(9-10):705-9. PubMed ID: 17466963
[TBL] [Abstract][Full Text] [Related]
7. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
8. Oxidative status and serum PON1 activity in beta-thalassemia minor.
Selek S; Aslan M; Horoz M; Gur M; Erel O
Clin Biochem; 2007 Mar; 40(5-6):287-91. PubMed ID: 17296173
[TBL] [Abstract][Full Text] [Related]
9. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus.
Ali EM; Shehata HH; Ali-Labib R; Esmail Zahra LM
Clin Biochem; 2009 Sep; 42(13-14):1394-400. PubMed ID: 19538950
[TBL] [Abstract][Full Text] [Related]
10. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients.
Kotur-Stevuljevic J; Spasic S; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Stefanovic A; Vujovic A; Memon L; Kalimanovska-Ostric D
Clin Biochem; 2008 Sep; 41(13):1067-73. PubMed ID: 18634772
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
[TBL] [Abstract][Full Text] [Related]
12. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
[TBL] [Abstract][Full Text] [Related]
13. Effects of peritoneal-and hemodialysis on levels of plasma protein and lipid oxidation markers in diabetic patients.
Sozer V; Korkmaz Guntas G; Konukoglu D; Dervisoglu E; Gelisgen R; Tabak O; Kalender B; Uzun H
Minerva Med; 2013 Feb; 104(1):75-84. PubMed ID: 23392540
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
Bahrehmand F; Vaisi-Raygani A; Rahimi Z; Ahmadi R; Kiani A; Tavilani H; Vaisi-Raygani H; Pourmotabbed T
Lupus; 2014 Mar; 23(3):263-72. PubMed ID: 24399815
[TBL] [Abstract][Full Text] [Related]
15. Serum lipid profile paraoxonase and arylesterase activities in psoriasis.
Toker A; Kadi M; Yildirim AK; Aksoy H; Akçay F
Cell Biochem Funct; 2009 Apr; 27(3):176-80. PubMed ID: 19330810
[TBL] [Abstract][Full Text] [Related]
16. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein.
Javadzadeh A; Ghorbanihaghjo A; Bahreini E; Rashtchizadeh N; Argani H; Alizadeh S
Retina; 2012 Apr; 32(4):658-66. PubMed ID: 22030834
[TBL] [Abstract][Full Text] [Related]
17. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.
Can Demirdöğen B; Türkanoğlu A; Bek S; Sanisoğlu Y; Demirkaya S; Vural O; Arinç E; Adali O
Clin Biochem; 2008 Jan; 41(1-2):1-9. PubMed ID: 17920578
[TBL] [Abstract][Full Text] [Related]
18. PON1 status in haemodialysis patients and the impact of hepatitis C infection.
Horoz M; Aslan M; Selek S; Koylu AO; Bolukbas C; Bolukbas FF; Celik H; Erel O
Clin Biochem; 2007 Jun; 40(9-10):609-14. PubMed ID: 17335792
[TBL] [Abstract][Full Text] [Related]
19. Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with chronic adenotonsillitis.
Koc S; Aksoy N; Bilinc H; Duygu F; Uysal IÖ; Ekinci A
Int J Pediatr Otorhinolaryngol; 2011 Nov; 75(11):1364-7. PubMed ID: 21893350
[TBL] [Abstract][Full Text] [Related]
20. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients.
Bounafaa A; Berrougui H; Ikhlef S; Essamadi A; Nasser B; Bennis A; Yamoul N; Ghalim N; Khalil A
Clin Biochem; 2014 Dec; 47(18):318-25. PubMed ID: 25218815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
